A homogeneous substrate-labeled fluorescent immunoassay has been developed to measure amikacin levels in human serum. Amikacin is covalently labeled with the fluorogenic enzyme substrate ,B-galactosyl-umbelliferone. This 8-galactosylumbelliferone-amikacin conjugate is nonfluorescent under assay conditions until it is hydrolyzed by 16-galactosidase to yield a fluorescent product. When antiserum to amikacin binds the substrate-labeled drug, the antibody complex formation inhibits hydrolysis of the fluorogenic substrate. Reaction mixtures containing a constant level of substrate-labeled amikacin and a limiting amount of antiserum enable labeled and unlabeled amikacin to compete for the antibody-binding sites. Unbound substrate-labeled drug is hydrolyzed by the enzyme to release a fluorescent product that is proportional to the unlabeled amikacin concentration. The amikacin levels found in clinical serum samples with this method were comparable (r = 0.987) to those obtained by radioimmunoassay. The fluorescent immunoassay is rapid and simple to perforn and requires only 2 t,l of serum.
A homogeneous substrate-labeled fluorescent immunoassay has been developed to measure amikacin levels in human serum. Amikacin is covalently labeled with the fluorogenic enzyme substrate ,B-galactosyl-umbelliferone. This 8-galactosylumbelliferone-amikacin conjugate is nonfluorescent under assay conditions until it is hydrolyzed by 16-galactosidase to yield a fluorescent product. When antiserum to amikacin binds the substrate-labeled drug, the antibody complex formation inhibits hydrolysis of the fluorogenic substrate. Reaction mixtures containing a constant level of substrate-labeled amikacin and a limiting amount of antiserum enable labeled and unlabeled amikacin to compete for the antibody-binding sites. Unbound substrate-labeled drug is hydrolyzed by the enzyme to release a fluorescent product that is proportional to the unlabeled amikacin concentration. The amikacin levels found in clinical serum samples with this method were comparable (r = 0.987) to those obtained by radioimmunoassay. The fluorescent immunoassay is rapid and simple to perforn and requires only 2 t,l of serum.
Amikacin is a semisynthetic aminoglycoside antibiotic currently administered for the treatment of severe infections of gram-negative bacteria. Like gentamicin and tobramycin, amikacin is effective within a narrow therapeutic range of serum concentrations above which the drug can be considered potentially toxic (1, 5) . Peak levels of amikacin in serum are generally expected to be between 20 and 25 ,ug/ml, whereas the trough level should be 5 to 10 ,ug/ml (1) . Monitoring of the serum amikacin concentration during the course of treatment is usually justified for maintenance of a therapeutic yet nontoxic level of the drug.
Various assays for amikacin in serum have been reported in recent years. These methods include microbiological assays (9) , radioimmunoassay (7, 11) , and high-performance liquid chromatographic (8) and spectrophotometric techniques (10) . We have previously developed substrate-labeled fluorescent immunoassays (SLF1A) to measure the therapeutic levels of tobramycin (2), gentamicin (4) , and phenytoin (12) . We now report the extension of the SLFIA to the determination of amikacin levels in human serum.
The SLFIA for amikacin requires that the drug be labeled with ft-galactosyl-umbelliferone, a fluorogenic substrate for the enzyme , 8- Synthesis of the FAR. The synthetic scheme for preparation of the substrate-labeled amikacin derivative is presented in Fig. 1 . A 1.0-mmol amount (370 mg) of 7-f?-D-galactosyl-coumarin-3-carboxylic acid ( Fig. 1, I ; reference 4) and 1.0 mmol (120 mg) of Nhydroxysuccinimide were dissolved in 20 ml of dimethylformamide, and the solution was cooled to -6°C. After the addition of 1.0 mmol (210 mg) of N,N-dicylohexylcarbodiimide, the reaction was stirred for 24 h at -6°C. The reaction was then filtered to remove precipitated dicyclohexyl urea. The filtrate containing the activated ester (Fig. 1, II (Fig. 1, IV ) was then eluted with 1.5 M ammonium formate. Fractions (20 ml) were collected, and the absorbance at 343 nm was monitored. The appropriate fractions were pooled, concentrated on a rotary evaporator at 400C, and sublimed (0.10 mm of Hg at 40°C) to remove the ammonium formate.
Antiserum. Antiserum to amikacin was produced in rabbits as previously described (6), with an amikacin-bovine serum albumin conjugate.
Radioimmunoassay for amikacin. Amikacin concentrations were determined by radioimmunoassay with the Monitor Science Amikacin RIA Kit (Monitor Science Corp., Newport Beach, Calif.).
SLFIA for determination of serum amikacin levels. To perform the SLFIA, 3.0 ml of a reagent containing the antibody and enzyme was added to a series of reaction cuvettes. (The antibody-enzyme reagent prepared in 50 mM Bicine-0.1% azide, pH 8.5, contained 50 mU of ,B-galactosidase per ml and sufficient antiserum to decrease the fluorescence output to 13% of that in the absence of antiserum.) Samples of 100 pl of amikacin standards, controls, and unknowns (previously diluted 50-fold in buffer) were then added to the respective cuvettes. The reaction was initiated with the addition of 100 pl of FAR (0.007 absorbance units at 343 nm per ml in 5 mM sodium formate-0.1% sodium azide buffer, pH 3.5) followed by immediate mixing. The FAR was added to each cuvette at 15-s intervals until all of the reactions in the run were initiated. After the first reaction mixture had incubated for 20 min, the fluorescence intensity for this and subsequent cuvettes was measured at 15-s intervals. The unknown amikacin concentrations were determined from a standard curve of fluorescence versus amikacin concentration. (2, 12) . Levels of antiserum that inhibited the hydrolysis of FAR 80 to 90% after a 20-min incubation period resulted in the best standard curves. Reactions containing varying levels of amikacin, 0.15 U of ,B-galactosidase, and 7.1 p1 of antiserum to amikacin in a volume of 3.1 ml were initiated by the addition of 0.0007 absorbance units of FAR at 343 nm. The fluorescence was measured at various incubation times, and the results are presented in Fig. 3 . The curves on the left side of the figure show the percentage of the maximum attainable fluorescence (completely hydrolyzed FAR). The curves on the right (Fig. 3) Figure 3 also shows that acceptable curves were generated with incubation times between 10 min and 2 h; however, a 20-min incubation time is routine and was used for the studies described below.
RESULTS
Performance characteristics of the amikacin SLEIA. The precision of the amikacin SLFIA was evaluated by assaying amikacin serum controls at three levels in five replicates each for 10 runs. The data were pooled (N = 50) for determination of the intra-and interassay precision that is shown in Table 1 (Fig.  4) . As shown, the two methods correlate very well (r = 0.987).
Specificity of the amikacin SLIFA. The cross-reactivity of the antiserum was examined by measuring the dose-response of other aminoglycosides in the amikacin assay (Fig. 5) With one exception, all of the clinical serum specimens that we examined were below the concentration of the highest standard (40 tg/ ml). When a specimen contains amikacin exceeding 40 ug/ml, it can be diluted to a concentration that is within the range of the standard curve. The precision, recovery, and correlation studies indicate that the SLFIA for anikacin is comparable to radioimmunoassay.
Simultaneous administration of combinations of aminoglycosides is not routinely practiced; therefore, cross-reactivity with kanamycin or tobramycin does not present a problem when measuring amikacin serum levels.
The amikacin SLFIA offers many advantages including a non-radioactive label which does not require separation of the bound and free label. The assay is easily performed, rapid, and quantitative, and several drug assays are now possible with the same assay format.
